Fig. 1From: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in JapanPatient disposition. aOut of 243 patients, 1 patient in the placebo to sarilumab 150 mg group was not treated; therefore, 242 patients were included in the modified intent-to-treat population for the KAKEHASI study. AE adverse event, MTX methotrexate, q2w every 2 weeksBack to article page